1-Piperidineethanol, 4-hydroxy-α-(4-hydroxyphenyl)-β-methyl-4-phenyl-, (αS,βS)-, methanesulfonate, hydrate (1:1:3)
| Title | Journal |
|---|---|
| Traxoprodil decreases pentylenetetrazol-induced seizures. | Epilepsy research 20120601 |
| Behavioral deficits and cellular damage following developmental ethanol exposure in rats are attenuated by CP-101,606, an NMDAR antagonist with unique NR2B specificity. | Pharmacology, biochemistry, and behavior 20120101 |
| Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. | Anesthesiology 20110701 |
| Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. | The Journal of biological chemistry 20110304 |
| Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. | Experimental neurology 20101001 |
| Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-D-aspartate receptors. | The European journal of neuroscience 20100801 |
| Comments on 'An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder'. | Journal of clinical psychopharmacology 20090801 |
| An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. | Journal of clinical psychopharmacology 20081201 |
| Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. | Movement disorders : official journal of the Movement Disorder Society 20081015 |
| Amygdala infusions of an NR2B-selective or an NR2A-preferring NMDA receptor antagonist differentially influence fear conditioning and expression in the fear-potentiated startle test. | Learning & memory (Cold Spring Harbor, N.Y.) 20080201 |
| The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. | Behavioural pharmacology 20071201 |
| Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs. | Drug metabolism and disposition: the biological fate of chemicals 20070801 |
| Nitric oxide (NO) serves as a retrograde messenger to activate neuronal NO synthase in the spinal cord via NMDA receptors. | Nitric oxide : biology and chemistry 20070801 |
| Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. | The Journal of pharmacology and experimental therapeutics 20070501 |
| NR2B subunit exerts a critical role in postischemic synaptic plasticity. | Stroke 20060701 |
| Glutamate-based therapeutic approaches: NR2B receptor antagonists. | Current opinion in pharmacology 20060201 |
| Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. | Clinical pharmacokinetics 20060101 |
| The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. | Journal of neurotrauma 20051201 |
| Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. | The European journal of neuroscience 20050901 |
| Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20050720 |
| Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. | Psychopharmacology 20050401 |
| NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. | Current drug targets. CNS and neurological disorders 20050401 |
| Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model. | Pharmacology 20050101 |
| Characterization of N-methyl-D-aspartate receptor subunits responsible for postoperative pain. | European journal of pharmacology 20041025 |
| NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. | Neuropharmacology 20040801 |
| The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. | Experimental neurology 20040801 |
| Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. | Brain research 20040611 |
| Synthesis of 11C-labelled bis(phenylalkyl)amines and their in vitro and in vivo binding properties in rodent and monkey brains. | Biological & pharmaceutical bulletin 20040401 |
| The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. | Current medicinal chemistry 20040201 |
| Characterization of N-methyl-D-aspartate receptor subunits involved in acute ammonia toxicity. | Neurochemistry international 20040101 |
| The NMDA NR2B subunit-selective receptor antagonist, CP-101,606, enhances the functional recovery the NMDA NR2B subunit-selective receptor and reduces brain damage after cortical compression-induced brain ischemia. | Journal of neurotrauma 20040101 |
| Antioxidant-accelerated oxidative degradation: a case study of transition metal ion catalyzed oxidation in formulation. | Pharmaceutical development and technology 20040101 |
| The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. | European journal of pharmacology 20030829 |
| Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats. | Journal of neurosurgery 20030201 |
| Differential alterations in the expression of NMDA receptor subunits following chronic ethanol treatment in primary cultures of rat cortical and hippocampal neurones. | Neurochemistry international 20030101 |
| Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (+/-)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors. | Nuclear medicine and biology 20020701 |
| Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. | Neuropharmacology 20020301 |